Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675149 | 0.84 | ADORA2A (0.43) | ADORA2AADORA2B | |
| SCHEMBL204117 | 0.78 | ADORA2A (0.44) | ADORA2AADORA2BCHEK1FLT3PLK3 | |
| SCHEMBL13122054 | 0.78 | ADORA2A (0.44) | ADORA2AADORA2BCHEK1FLT3PLK3 | |
| SCHEMBL13122058 | 0.75 | ADORA2A (0.46) | ADORA2AADORA2BCHEK1FLT3PLK3 | |
| SCHEMBL1144559 | 0.75 | ADORA2A (0.42) | ADORA2AADORA2BCHEK1FLT3PLK3 | |
| SCHEMBL20667379 | 0.72 | ADORA2A (0.40) | ADORA2AADORA2BCHEK1FLT3PLK3 | |
| SCHEMBL1145133 | 0.70 | TTR (0.43) | ADORA2AADORA2B | |
| SCHEMBL13122070 | 0.69 | KCNH2 (0.33) | CHEK1FLT3PLK3 | |
| SCHEMBL13122195 | 0.68 | ADORA2A (0.46) | ADORA2AADORA2BP2RX7 | |
| SCHEMBL91441 | 0.68 | NTRK1 (0.43) | ADORA2AADORA2BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA2B 4/4885CHEK1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.